Neurocognition in Adult Congenital Heart Disease: How to Monitor and Prevent Progressive Decline.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 29 04 2019
revised: 18 06 2019
accepted: 18 06 2019
pubmed: 2 10 2019
medline: 29 5 2020
entrez: 2 10 2019
Statut: ppublish

Résumé

Children born with congenital heart disease (CHD) are now living to adulthood in unprecedented numbers and many will eventually live to become senior citizens. As care goals shift from surviving to thriving, a new focus on quality of life has emerged. Neurocognition and the ability to participate fully in society, form meaningful relationships, and collaborate effectively with the health care system are important considerations. As adults with CHD age, research regarding their cognitive function becomes prescient. The focus is now shifting from defining neurocognitive deficits in children with CHD to preventing neurocognitive decline in adults living with CHD. In this review, we describe the possible etiologies and predictors of neurocognitive decline in adults with CHD. We performed a comprehensive literature review to identify all of the current data available on neurocognitive function in adults with CHD. We summarize the available evidence by describing common deficits in this patient population and the potential effects of these deficits on adult functioning, health care decision-making, and long-term relationships with care providers. We review potential modifiable etiologies for progressive neurocognitive decline and suggest strategies for surveillance and prevention of the potential decline. We conclude that the current information available regarding the aging brain of adults with CHD and the effect of neurocognitive decline on morbidity and mortality is woefully insufficient. This review, therefore, provides a roadmap for future research endeavours to study neurocognition in older adults with CHD.

Identifiants

pubmed: 31570238
pii: S0828-282X(19)30441-6
doi: 10.1016/j.cjca.2019.06.020
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1675-1685

Informations de copyright

Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Michelle Keir (M)

Southern Alberta Adult Congenital Heart Clinic, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address: michelle.keir@albertahealthservices.ca.

Patricia Ebert (P)

Department of Psychology and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

Adrienne H Kovacs (AH)

Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.

Jonathan M C Smith (JMC)

BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Emily Kwan (E)

Department of Geriatric Medicine, University of Calgary, Calgary, Alberta, Canada.

Thalia S Field (TS)

Vancouver Stroke Program, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Marie Brossard-Racine (M)

School of Physical and Occupational Therapy, McGill University, Montreal, Quebec, Canada.

Ariane Marelli (A)

McGill Adult Unit for Congenital Heart Disease Excellence, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH